Vir Biotechnology Signs a License Agreement with Xencor to Utilize Xtend Fc Technology in Antibodies Targeting COVID-19

Vir Biotechnology Signs a License Agreement with Xencor to Utilize Xtend Fc Technology in Antibodies Targeting COVID-19

Shots:

  • Vir will get non-exclusive access to Xencor’s Xtend Fc technology for extending the half-life of novel Abs that the company is evaluating for treating patients with COVID-19, a disease caused by novel coronavirus SARS-CoV-2
  • Vir will be responsible for research, development, regulatory and commercial activities while Xencor continues to assess the impact of the COVID-19 pandemic on ongoing and planned clinical studies
  • In Aug’2019, the two companies collaborated under which Vir got a non-exclusive license to Xtend technology for utilizing it in developing & commercializing Abs targeting influenza and hepatitis B virus infection

Click here ­to­ read full press release/ article | Ref: Xencor | Image: VIR Biotechnology